Attorney Docket No. PHARMA-101

Appl. No. 10/565,322

Reply to Office communication of 7/22/2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: EVANGELOS KARAVAS

Serial No.: 10/565,322 Filed: 01/20/2006 Attorney Docket No.: PHARMA-101

Title: SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE

HYDROCHLORIDE

Office Communication Mailed: 7/22/2008

Confirmation No: 2221

ART UNIT 1614 Date Mailed: 11/21/2008

EXAMINER: SAVITHA M. RAO

Honorable Commissioner for Patents

P.O.Box 1450, Alexandria, VA 22313-1450

REQUEST FOR REFUND

At the initial filing of the above mentioned US National Stage under 35 USC 371 application, small entity status was indicated. In the response filed on 11/21/2008 accidentally large entity extension fees for a 3-month extension were submitted. Refund of the excess extension fees is requested. Please apply the refund as a credit to the credit card used for payment.

Respectfully submitted,

/Aliki K. Collins, Reg. No: 43,558/

Aliki K. Collins, Ph.D.

Reg. No. 43,558

AKC Patents, 215 Grove Street, Newton, MA 02466

TEL: 781-235-4407, FAX: 781-235-4409

Certificate of Mailing

Date of Deposit 11/21/2008

Name: Aliki K. Collins, Ph.D. Signature /Aliki K. Collins, Reg. No: 43,558/

I hereby certify under 37 CFR 1.10 that this correspondence is being electronically at the

USPTO on the date indicated above and is addressed to the Commissioner for Patents, P.

O. Box 1450, Alexandria, VA 22313-1450